IDEXX Laboratories (STU:IX1) Research & Development: €222 Mil (TTM As of Mar. 2026)


STU:IX1 IDEXX Laboratories Inc STU:IX1
96 GF Score
Price €483.60
GF Value €555.42
Valuation Modestly Undervalued
View Full Analysis

What is IDEXX Laboratories Research & Development?

IDEXX Laboratories STU:IX1 +1.81% 96 Research & Development is €222 Mil as of Mar. 2026. GuruFocus rates STU:IX1 with a GF Score™ of 96/100 and a GF Value™ of €555.42 (Modestly Undervalued).

Research & Development is the aggregate amount of research and development expenses during the year. IDEXX Laboratories's Research & Development for the three months ended in Mar. 2026 was €57 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €222 Mil.

IDEXX Laboratories  (STU:IX1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

IDEXX Laboratories Research & Development Related Terms

IDEXX Laboratories Research & Development Historical Data

* Premium members only.

The historical data trend for IDEXX Laboratories's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories Research & Development Chart

IDEXX Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 142.49 240.55 175.10 209.90 214.53

IDEXX Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.63 53.67 54.03 57.08 56.91
STU:IX1
96GF Score
IDEXX Laboratories Inc STU:IX1
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDEXX Laboratories Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €222 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €222 Mil mean?
IDEXX Laboratories (STU:IX1) has a Research & Development of €222 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on IDEXX Laboratories and its competitors.
Is IDEXX Laboratories' Research & Development too high?
IDEXX Laboratories' current Research & Development is €222 Mil. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Research & Development compare to A and WAT?
IDEXX Laboratories' Research & Development of €222 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current Research & Development is €222 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (STU:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €555.42, compared to a current price of €483.60 — trading 12.9% below its estimated fair value. The current Research & Development is €222 Mil. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For IDEXX Laboratories (STU:IX1), the current Research & Development is €222 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (STU:IX1) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of €483.60 is trading 12.9% below its estimated GF Value™ of €555.42. GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.

Key valuation signals for STU:IX1:

  • Research & Development: €222 Mil
  • GF Value™: €555.42 vs. price of €483.60 (12.9% below fair value)
  • GF Score™: 96/100

No single metric tells the full story. See the STU:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score

Get the complete analysis for STU:IX1

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€483.60
Price
€555.42
GF Value